Phase 3 hepatocellular carcinoma fail crushes Onxeo by Nick Paul Taylor Tuesday, September 12, 2017 The setback wiped about 50% off Onxeo’s share price as investors adjusted to the diminished expectations for the doxorubicin-loaded nanoparticles.
ASCO: Chi-Med touts fruquintinib's phase 3 safety edge by Angus Liu Monday, June 5, 2017 In a late-stage study presented at ASCO, Chi-Med’s fruquintinib showed it could help relapsed patients with advanced colorectal cancer live longer.
